Core Viewpoint - The company, Shuanglu Pharmaceutical, confirmed its normal operational status and ongoing business activities, including recent acquisitions in the healthcare sector [1] Group 1: Company Operations - Shuanglu Pharmaceutical's main business activities include technology development, consulting, transfer, and hospital management [1] - The company has acquired Jinmei General Hospital (a tertiary hospital) and several secondary and primary hospitals, as well as community health service stations through its subsidiary, Shanxi Jinmei Guoke New Mile Medical Management Co., Ltd [1] - The company stated that it is currently in a normal operational phase, with all situations being normal [1]

Group 1 - The core point of the article highlights a significant increase in the stock price of China Health Group, which rose by 14.55% to 0.63 CNY per share, with a trading volume of 1.0841 million CNY as of 09:30 on July 31 [1] - China Health Group is primarily engaged in the investment services of the health industry in mainland China, including hospital management, distribution and services of medical devices and consumables, and the selection and distribution of pharmaceutical products [1] - The company is one of the early foreign investment institutions to enter the medical field in mainland China, with its headquarters located in Hong Kong [1] Group 2 - As of the 2024 annual report, China Health Group reported a total operating revenue of 35.9378 million CNY and a net profit of -62.5586 million CNY [2]